Common Iliac Artery Aneurysm
Conditions
Keywords
Lifetech, Iliac Bifurcation Stent Graft System, Endovascular Repair
Brief summary
The objective of this study is to evaluate the Safety and Efficacy of the G-iliac Iliac Bifurcation Stent Graft System for Endovascular Repair of Common Iliac Artery Aneurysms(CIAA).
Detailed description
The physician shall strictly follow the clinical study protocol and shall not deviate from or substantially change the protocol. However, in case of emergency such as immediate risk to the subjects, which needs tobe eliminated immediately, it may be reported in written form afterwards. During the course of the study,documents such as amendments to the clinical study protocol and informed consent, requests for deviation,and resumption of the suspended clinical study shall be subject to the written approval of the Ethics Committee.
Interventions
DEVICEliac Bifurcation Stent Graft System
to evaluate the Safety and Efficacy of the G-iliac Iliac Bifurcation Stent Graft System for Endovascular Repair of Common Iliac Artery Aneurysms(CIAA)
Sponsors
Lifetech Scientific (Shenzhen) Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Patients who have undergone implantation of the iliac bifurcation stent graft system; * Patients with complete medical records
Exclusion criteria
* Patients with ruptured aortic aneurysm; * Patients with infected or mycotic aortic aneurysm; * Patients with connective tissue diseases, such as systemic lupus erythematosus, Marfan syndrome, Ehlers-Danlos syndrome, or Behcet's disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The Incidence of Major Adverse Events (MAE) within 30 Days postoperatively. | within 30 Days postoperatively | Major Adverse Events (MAE) are defined as follows: all-cause mortality related to iliac artery aneurysms associated with the surgery or device, myocardial infarction, renal failure, respiratory failure, paraplegia, stroke, and intestinal ischemia. |
| he patency rate of internal iliac artery (IIA) at 12 months postoperatively | at 12 months postoperatively | The patency rate of internal iliac artery (IIA) defined as blood flow without occlusion maintained through the device without intervention |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The incidence of malfunction before discharge and at 12 months postoperatively. | before discharge and at 12 months postoperatively. | Malfunction means the failure of a device to meet its performance specifications or otherwise perform as intended.Performance specifications include all claims made in the labeling for the device. The intended performance of a device refers to the intended use for which the device is labeled or marketed. |
| The incidence of conversion to open surgery or secondary interventional procedures due to iliac artery aneurysms before discharge and at 12 months postoperatively. | before discharge and at 12 months postoperatively | Notes: Due to the patient's condition, the surgeon's choice of staged reconstruction does not constitute a secondary surgical intervention. |
| The immediate technical success during intraoperative procedures. | during intraoperative procedures | immediate technical success refers to successful delivery of the stent to the intended location by the delivery system, successful deployment of the stent, and safe removal of the delivery system. Additionally, angiography should show unobstructed blood flow within the stent, with no stent kinking, folding, narrowing, or occlusion. |
| Incidence rate of Type I/III endoleak caused by the iliac bifurcation system that necessitate reintervention before discharge and at 12 months postoperatively. | before discharge and at 12 months postoperatively. | Type I endoleak, also known as peri-graft endoleak or graft-related endoleak, refers to the leakage caused by the inability of the stent graft to tightly adhere to the autologous vessel, leading to continuous blood flow into the aneurysm sac. This includes proximal and distal Type I endoleaks. Type III endoleak refers to the leakage caused by the inability of the stent graft's own connectors to tightly adhere or the rupture of the artificial vessel, which results in continuous blood flow into the aneurysm sac. |
| Device-related adverse events before discharge and at 12 months postoperatively | before discharge and at 12 months postoperatively. | Device-related adverse events are those situations that are ultimately determined to be definitely related, possibly related, or indeterminate with respect to the study device. |
Countries
China
Outcome results
None listed